NEW YORK, NY - June 26, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025 (the “Class Period”).
If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 25, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
Hims & Hers operates a telehealth platform that connects customers to licensed healthcare professionals and offers a range of both prescription and non-prescription health and wellness products.
On May 20, 2024, the Company announced the addition of GLP-1 injections to its comprehensive weight loss portfolio. Hims & Hers stated that “[p]roviding access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications.”
On April 29, 2025, Hims & Hers announced the first-step in a long-term collaboration with Novo Nordisk by providing “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.”
Then, on June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating the collaboration with Hims & Hers, including that “direct access to Wegovy® will no longer be available” to Hims & Hers, “based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.” The press release stated that Hims & Hers “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.’” The press release further stated “[b]ased on Novo Nordisk’s investigation, the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China” that the “FDA has never authorized or approved” according to a report from the Brookings Institute.
Following this news, the price of Hims & Hers stock fell $22.24 per share, over 34%, to close at $41.98 per share on June 23, 2025.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.